SCHEMBL3300847

SCHEMBL3300847

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2ccc(C(F)(F)F)cc2Cl)CC3)cc1

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 16/20 0.51
PDE5A O76074 1/20 0.41
MGAT2 Q10469 1/20 0.41
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3303208 0.95 PRLHR (0.51) PRLHRPDE5A
SCHEMBL3297793 0.91 PRLHR (0.50) PRLHRMGAT2
SCHEMBL3300421 0.91 PRLHR (0.50) PRLHRPDE5A
SCHEMBL3299089 0.90 PRLHR (0.46) PRLHRPDE5A
SCHEMBL3295383 0.89 PRLHR (0.49) PRLHRPDE5A
SCHEMBL3299646 0.89 PRLHR (0.49) PRLHRPDE5A
SCHEMBL3300072 0.89 PRLHR (0.53) PRLHRMGAT2
SCHEMBL3299804 0.88 LMNA (0.50) PRLHR
SCHEMBL3297279 0.88 PRLHR (0.49) PRLHRPDE5A
SCHEMBL3296546 0.87 PRLHR (0.46) PRLHRMGAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885PDE5A 2992/4885MGAT2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.